• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

May 9, 2018 By Celyad

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies,  today announced that the company will present recent advances in Celyad’s pipeline at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held May 16–19, 2018, in Chicago.

Poster presentations will highlight the recent developments of Celyad’s pipeline in autologous and allogeneic platforms to address cancers. The oral presentation will give updated data of the ongoing THINK Phase 1 trial with the case report of a CYAD-01 associated complete response in one relapsed/refractory AML patient, including observations concerning the modulation of systemic chemokines during the course of treatment.

David Gilham, VP of Research and Development at Celyad, commented: ‘Our presentations at the 2018 meeting of the ASGCT will share our increasing knowledge around our lead NKG2D CAR T cell candidate along with discussing our pipeline including the B7H6 CAR T program and our allogeneic platform. These presentations are the culmination of an intensive level of activity within our R&D group. We anticipate that this will lead to a series of assets that will enter clinical stage testing during 2019.’

Presentation Details:

TitleEarly Signs of Clinical Activity in AML Patients Receiving NKG2D CAR-T Cell Therapy in the Absence of Pre-Conditioning Chemotherapy: An Alternative Strategy to CAR-T Cell TherapyLink
Number967
CategoryCancer-Immunotherapy, Cancer Vaccines
Session412 Advancements in T Cell-Based Therapies
Session Date & TimeSaturday, May 19, 2018, 11:00 AM CDT
LocationContinental Ballroom ABC

Posters Details:

Poster titleFunctional screening of a B7H6 specific chimeric antigen receptor (CAR)Link
Poster Number123
CategoryCancer – Immunotherapy, Cancer Vaccines I      
SessionExhibit Hall Welcome Reception & Poster Session I
Session Date & TimeWednesday, May 16, 2018, 5:30 PM CDT
LocationStevens Salon C, D
Poster TitleOvercoming target-driven fratricide for CAR-T cell therapyLink
Poster Number119
CategoryCancer-Immunotherapy, Cancer Vaccines
SessionExhibit Hall Welcome Reception & Poster Session I
Session Date & TimeWednesday, May 16, 2018, 5:30 PM CDT
LocationStevens Salon C, D
//Poster TitleExpression of a TIM8 peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approachLink
Poster Number457
CategoryCell Therapies  
SessionExhibit Hall Networking Reception & Poster Session II
Session Date & TimeThursday, May 17, 2018, 5:15 PM CDT
LocationStevens Salon C, D
Download press release(s)
Communiqué de presse
Press Release
Persbericht

Filed Under: Corporate, Non-regulated

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use